June 18, 2007 – Milan, Italy – The 14-week multicenter, open label, titration-to-goal GEMINI-AALA study in patients with hypertension and dyslipidemia showed that a single pill with amlodipine/atorvastatin with eight different doses showed that 52% of patients reached both blood pressure and LDL-C goals, 61.3% reached blood pressure goals, and 87.1% reached LDL-C goals. These reductions were similar across different racial groups. Prof. S. Erdine, Istanbul, Turkey, presented the results of the GEMINI-AALA study.

Of the 1,649 patients from 27 countries across 5 countries, 52% were Asian. In addition to the risk of hypertension and dyslipidemia, 91.4% had 1 or more risk factor and 62% had CHD or risk equivalent. The primary endpoint was the percentage of patients who reached the JNC VII goals for blood pressure (<140/90 mmHg or <130/80 mmHg) and LDL-C (<2.4-4.1 mmol/l).

The mean calculated 10-year Framingham risk of CHD was reduced by about 50% from baseline, across all racial group, according to a post-hoc analysis.

Treatment with the combined pill was safe and well tolerated, with peripheral edema (9.8%) and respiratory tract infection (5%) the most common adverse effects related to treatment.